BIIB Q3 2020 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.4B-6.2% YoY

Gross Profit

$2.9B86.7% margin

Operating Income

$1.1B32.2% margin

Net Income

$702M20.8% margin

EPS (Diluted)

$4.46

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.1B

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$24.9B

Total Liabilities

$14.2B

Stockholders' Equity

$10.8B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$3.6B	-6.2%
Gross Profit	$2.9B	$3.2B	-7.7%
Operating Income	$1.1B	$1.8B	-39.9%
Net Income	$702M	$1.5B	-54.6%

Revenue Segments

MS Product Revenues

$2.0B45%

Fumarate

$968M22%

TYSABRI product

$517M12%

SPINRAZA

$494M11%

Interferon

$474M11%

Geographic Segments

UNITED STATES

$1.5B56%

Non-US

$1.2B44%